Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK ; day:28 ; month:6 ; year:2021 ; pages:1-15
PharmacoEconomics - open ; (28.6.2021), 1-15
- Creator
-
Russell-Smith, T. Alexander
Brockbank, James
Mamolo, Carla
Knight, Christopher
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-021-00278-3
- URN
-
urn:nbn:de:101:1-2021101019390266227046
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Russell-Smith, T. Alexander
- Brockbank, James
- Mamolo, Carla
- Knight, Christopher
- SpringerLink (Online service)
Other Objects (12)
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Sequence analysis of the NUMB gene in chronic myeloid leukaemia patients
Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment
Identification of CDX2 targets in acute myeloid leukaemia
Spontaneous chest wall haematoma in chronic myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Survival with chronic myeloid leukaemia after failing milestones
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: A UK-based cost-utility analysis
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Sequence analysis of the NUMB gene in chronic myeloid leukaemia patients
Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment
Identification of CDX2 targets in acute myeloid leukaemia
Spontaneous chest wall haematoma in chronic myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Survival with chronic myeloid leukaemia after failing milestones
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: A UK-based cost-utility analysis
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Sequence analysis of the NUMB gene in chronic myeloid leukaemia patients
Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment
Identification of CDX2 targets in acute myeloid leukaemia
Spontaneous chest wall haematoma in chronic myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Survival with chronic myeloid leukaemia after failing milestones
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: A UK-based cost-utility analysis
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy